  
CONFIDENTIAL  0 RATIONAL OPTIMIZATION OF TACS FOR TARGETING THALAMO-CORTICAL OSCILLATIONS: SINGLE SESSION IN A DEPRESSIVE EPI[INVESTIGATOR_182051], EXPERIMENT III  Funding Mechanism: NIMH R01 Principal Investigator: [INVESTIGATOR_61560], PhD Co-Investigator: Crystal Schiller, PhD; David Rubinow, MD Protocol Number: N/A Version Number: 1.0 Date: NCT Number: 4/29/19  [STUDY_ID_REMOVED]           Initial version: 4/29/19 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140583] OF ABBREVIATIONS ...................................................................................................................... 4 STUDY SUMMARY ................................................................................................................................ 5 1 KEY ROLES ..................................................................................................................................... 6 1.1 INDIVIDUALS .................................................................................................................................. 6 1.2 INSTITUTIONS ................................................................................................................................. 6 1.3 OPTIONAL ..................................................................................................................................... 6 1.4 FUNDING SOURCES ......................................................................................................................... 7 2 INTRODUCTION ............................................................................................................................. 8 2.1 BACKGROUND ................................................................................................................................ 8 2.2 INVESTIGATIONAL AGENT ................................................................................................................. 9 2.3 DOSE RATIONALE ............................................................................................................................ 9 2.4 STUDY AIMS/HYPOTHESES ............................................................................................................... [ADDRESS_1140584] SELECTION AND WITHDRAWAL ...................................................................................... 10 3.1 INCLUSION CRITERIA ...................................................................................................................... 10 3.2 EXCLUSION CRITERIA ..................................................................................................................... 10 3.3 STRATEGIES FOR RECRUITMENT AND RETENTION ................................................................................. 11 3.3.1 RECRUITMENT ................................................................................................................................... 11 3.3.2 RETENTION ....................................................................................................................................... 11 4 BASIC STUDY DESIGN ................................................................................................................... 12 4.1 TREATMENT ASSIGNMENT PROCEDURES ............................................................................................ 12 4.1.1 RANDOMIZATION PROCEDURES ............................................................................................................ 12 5 STUDY SCHEDULE ........................................................................................................................ 14 5.1 SCREENING .................................................................................................................................. 14 5.2 STUDY VISITS ............................................................................................................................... 14 5.4.1 STUDY VISIT ...................................................................................................................................... 14 5.4.3 UNBLINDING PROCEDURES .................................................................................................................. 15 6 STUDY PROCEDURES/EVALUATIONS ............................................................................................ 16 6.1 SELF-REPORT MEASURES ................................................................................................................. 16 6.2 SPECIAL ASSAYS OR PROCEDURES ...................................................................................................... 16 6.3 SAFETY MEASURES ........................................................................................................................ 16 6.4 LABORATORY EVALUATIONS ............................................................................................................ 16 6.4.1 SCREENING LABORATORY EVALUATIONS ................................................................................................. 17 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140585] ................................ 20 8 POTENTIAL RISKS AND BENEFITS .................................................................................................. 21 8.1 BENEFITS TO SUBJECTS AND SOCIETY ................................................................................................. 21 8.2 POTENTIAL RISKS .......................................................................................................................... 21 8.2.1 PSYCHOLOGICAL ................................................................................................................................ 21 8.2.2 PHYSICAL .......................................................................................................................................... 21 8.3 REFERRALS FOR MEDICAL FOLLOW-UP OR PSYCHOLOGICAL COUNSELING .................................................. 22 8.3.1 PREGNANCY FOLLOW-UP .................................................................................................................... 22 9 DATA AND SAFETY MONITORING ................................................................................................ 23 9.1 FROHLICH LAB MONITORING PLAN ................................................................................................... 23 9.2 SAFETY OVERSIGHT ....................................................................................................................... 23 9.3 EARLY WITHDRAWAL OF PARTICIPANTS ............................................................................................. 23 9.3.1 REASONS FOR WITHDRAWAL ............................................................................................................... 23 9.3.2 DATA COLLECTION AND FOLLOW-UP FOR WITHDRAWN PARTICIPANTS ....................................................... 24 9.4 TERMINATION OF STUDY ................................................................................................................ 24 10 SAFETY & REPORTING ................................................................................................................ [ADDRESS_1140586] KEEPI[INVESTIGATOR_1645] ................................................................................... 29 12.1 PHI AND HIPAA ........................................................................................................................ 29 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140587] (IRB) ............................................................................................. 32 13.3 INFORMED CONSENT PROCESS ...................................................................................................... 32 13.4 EXCLUSION OF WOMEN, MINORITIES, AND CHILDREN (SPECIAL POPULATIONS) ....................................... 33 13.5 PARTICIPANT CONFIDENTIALITY ..................................................................................................... 33 13.6 STUDY DISCONTINUATION ............................................................................................................ 33 14 PUBLICATION POLICY ................................................................................................................ 34 15 LITERATURE REFERENCES .......................................................................................................... 35 APPENDIX A: SCHEDULE OF EVENTS ................................................................................................... 38 APPENDIX B: AE REPORT FORM ......................................................................................................... 39 APPENDIX C: IRB AMENDMENT TRACKING LOG ................................................................................. 41 APPENDIX D: AE REPORT FORM ......................................................................................................... 41 APPENDIX F: NOTE TO FILE ................................................................................................................. 44 APPENDIX G: TELEPHONE SCRIPT ....................................................................................................... 45 APPENDIX H: TRAINING LOG .............................................................................................................. 45    
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140588] OF ABBREVIATIONS AE Adverse Event/Adverse Experience ANOVA Analysis of Variance CFR Code of Federal Regulations CNS Central Nervous System Co-I Co-Investigator CRF CTRC Case Report Form Clinical Trials Research Center  DMV Department of Motor Vehicles eCRF Electronic Case Report Form EEG Electroencephalogram FDA Food and Drug Administration GCP Good Clinical Practice HIPAA Health Insurance Portability and Accountability Act Hz IAF Hertz Individualized Alpha Frequency ICF Informed Consent Form LAR Legally Authorized Representative NIH National Institutes of Health NRB Neurosciences Research Building OHRE Office of Human Research Ethics OHRP Office for Human Research Protections PHI Protected Health Information PI [INVESTIGATOR_423893]/Serious Adverse Experience tACS Transcranial Alternating Current Stimulation tDCS Transcranial Direct Current Stimulation TMS Transcranial Magnetic Stimulation UE Unexpected Event UNC University of North Carolina UNC-CH University of North Carolina at Chapel Hill US [LOCATION_002]            
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  5 STUDY SUMMARY Title Rational optimization of tACS for targeting thalamo-cortical oscillations: Single session in a depressive epi[INVESTIGATOR_1865], Experiment III Short Title SSDE Protocol Number Version 1.0   Phase Pi[INVESTIGATOR_533460]-blind, randomized, active sham controlled Study Duration This study will take 18 months to complete. Study Center(s) This is a single-site study performed at the University of North Carolina at Chapel Hill.  Objectives (Purpose) The primary objective of this study is to investigate the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders.  Number of Subjects 80 Diagnosis and Main Inclusion Criteria Eligible participants will be adults between the ages of 18-65 in a current depressive epi[INVESTIGATOR_822556]-matched health adults with no history of mental or psychiatric illness.   Description of Intervention (Procedures/methods) The participants will be randomized into one of two arms: either 40 minutes of sham tACS or 40 minutes of IAF tACS while in a relaxed, yet experimentally controlled state, by [CONTACT_84022] a nature movie such as “Reefscape” during stimulation. Related IRB Applications 16-1911    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  6 1 KEY ROLES 1.1 INDIVIDUALS Principal Investigator [INVESTIGATOR_61560], PhD Co-Investigator Crystal Schiller, PhD David Rubinow, MD Medical Monitor Crystal Schiller, PhD  Flavio Frohlich, PhD – Principal Investigator [CONTACT_11604] – Chapel Hill Department of Psychiatry Email: [EMAIL_1219] Office: 4109F Neuroscience Research Building Phone: ([PHONE_4786]  Crystal Schiller, PhD – Co-Investigator, Medical Monitor UNC – Chapel Hill Department of Psychiatry  David Rubinow, MD – Co-Investigator UNC – Chapel Hill Department of Psychiatry  Morgan Alexander – Project Manager/Study Coordinator UNC – Chapel Hill  Email:  [EMAIL_1669] Office: Medical School Wing C – Room 233 Phone:  ([PHONE_17178]  Justin Riddle – Research Assistant UNC – Chapel Hill  Email:  [EMAIL_5384] Office: Mary Ellen Jones Building   Charles Zhou, BS – Research Assistant Neuroscience Center Email: [EMAIL_1670] Office: Neuroscience Research Building Phone: ([PHONE_17179]   1.2 INSTITUTIONS The University of North Carolina at Chapel Hill 1.3 OPTIONAL IRB 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  7 The University of North Carolina – Chapel Hill Medical School Building [ADDRESS_1140589] CB #7097 Chapel Hill, NC [ZIP_CODE] ([PHONE_2658] 1.[ADDRESS_1140590]: Sponsor Name [CONTACT_456112]/Grant Number NIH National Institute of Mental Health (NIMH) N/A Federal N/A N/A R01MH101547 External Funding: This project is externally funded but UNC-CH is not the direct recipi[INVESTIGATOR_61563]. UNC-CH Funding: This project is not funded through UNC-CH. Classified: This project is not classified.   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  8 2 INTRODUCTION This document is a protocol for a human research study. This study is to be conducted according to U.S. and international standards of Good Clinical Practice (FDA Title 21 Part 312 and International Conference on Harmonization guidelines), applicable government regulations and Institutional research policies and procedures. 2.1 BACKGROUND The objective is to use non-invasive electrophysiology to demonstrate that transcranial alternating current stimulation (tACS) indeed modulates human thalamo-cortical alpha oscillations. To achieve translational relevance, we will evaluate the stimulation patterns not only in occipi[CONTACT_1639]-parietal cortex, where alpha oscillations are maximal, but also in frontal areas, where altered alpha oscillations correlate with impaired approach motivation. The rationale for this aim is that validation in humans of tACS based on the mechanistic insights on modulation of thalamo-cortical network dynamics will enable and accelerate the further study of optimized tACS in healthy and patient populations. The study of alpha oscillations (~10 Hz) as a brain stimulation target is significant due to its central role in mediating long-range functional connectivity (von Stein & Sarnthein, 2000), attentional modulation of cortical information processing (Saalmann, Pi[INVESTIGATOR_541476], Wang, Li, & Kastner, 2012), and disease states such as depression (Leuchter, Hunter, Krantz, & Cook, 2015) and autism (Murias, Webb, Greenson, & Dawson, 2007). Pursuing alpha oscillations is further motivated (1) by [CONTACT_822568]-intensity stimulation modalities for mood disorders that target alpha oscillations, such as synchronizing transcranial magnetic stimulation (sTMS; Frohlich, 2015; Leuchter, Cook, et al., 2015; Leuchter, Cook, Jin, & Phillips, 2013) and (2) by [CONTACT_822569] 10Hz repetitive TMS entrains alpha oscillations (Thut et al., 2011). Previous tACS studies from other groups have shown that 10Hz tACS is capable to increase alpha oscillations during tACS application and in the post stimulation interval compared to a non-stimulation baseline (Helfrich et al., 2014; Neuling, Rach, & Herrmann, 2013; Vossen, Gross, & Thut, 2015; Zaehle, Rach, & Herrmann, 2010). However, questions of significant importance have remained unanswered. It is unclear to what extent the findings were contaminated by [CONTACT_822570] (e.g. drowsy vs. alert) independent of stimulation.We will answer this question by [CONTACT_822571][INVESTIGATOR_115726]. Measurements of pupil diameter in humans index arousal levels that correlate with the activation of the noradrenergic system (Koss, 1986; Murphy, Robertson, Balsters, & O'Connell R, 2011) and power of the alpha oscillation (Hong, Walz, & Sajda, 2014). In addition, alpha tACS studies measuring EEG had rather small sample sizes (12-30 participants). Experiment [ADDRESS_1140591] of alpha tACS and its state dependence in a bigger dataset of healthy participants using comparable electrode locations (over occipi[INVESTIGATOR_531116]). Furthermore, we use for the first time a high density EEG (128 electrodes) that will allow to explore the spatial distribution of the effect of alpha tACS. Experiment [ADDRESS_1140592] the interaction between tACS and alpha oscillations by [CONTACT_822572] (arousal/drowsiness). However, several studies have shown that frontal alpha oscillation properties (strength, distribution etc) reflect cognitive processing and impairments in frontal alpha are implicated in psychiatric disorders (Klimesch 2012, Allen and Reznik 2015). Hence, we target the frontal alpha oscillations in Experiments 2 and 3.  Despi[INVESTIGATOR_822557]-tACS, it is unclear if target engagement for frontal alpha oscillations follows the same principles. In addition, it remains untested if tACS also engages pathologically altered alpha oscillations. Considering that patients with reduced approach motivation, such as depression, show altered frontal alpha power topographies (e.g. asymmetry) answering these questions is of fundamental importance (Debener et al., 2000). Our second experiment using stimulation electrodes over the frontal cortex in patients with decrease in approach motivation will directly address these questions. 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  9 On purpose, we refrain from using the clinical diagnosis of major depressive disorder but rather (following the RDoC principles; Craske 2012) cast a wider net to capture a more complete set of patients that are likely to have altered alpha oscillations. Changes in the symmetry between alpha power in the left and the right hemisphere have been reported to be correlated with a decrease in approach motivation as measured by [CONTACT_822573] (de Pascalis et al. 2013), which corresponds to a construct in the RDoC domain of positive valence. In addition, patients with depresssion (MDD and Bipolar depression) often rate higher in the BIS scale compared to healthy individuals (Kasch et al. 2002, Johnson et al. 2003). In this study, we aim to study the effect of transcranial alternating current stimulation on the alpha oscillation in healthy individuals as well as patients who show altered alpha dynamics.   2.2 INVESTIGATIONAL AGENT Transcranial Alternating Current Stimulation (tACS) is one method that has been demonstrated to enhance alpha oscillations in healthy participants by [CONTACT_822574] (Lustenberger et al, 2015).  2.[ADDRESS_1140593] experiment under this protocol. 2.4 STUDY AIMS/HYPOTHESES Central Hypothesis: Non-invasive brain stimulation that enhances alpha oscillation increases endogenous alpha power and reduces frontal alpha asymmetry when present. Aim 1: Our first objective is to study the effect of tACS in healthy humans on neurophysiology measured using hdEEG  Aim 2: Our third objective is to study the effect of tACS on neurophysiology in patients with mood disorders and impaired alpha oscillations and compare it to the effect in healthy humans   
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140594] meet all of one of the following sets of criteria: Inclusion Criteria for individuals with depressed mood • Ages 18-65 years • Hamilton Depression Rating Scale score >8 • Capacity to understand all relevant risks and potential benefits of the study (informed consent) • Low suicide risk which will be determined through the use of both the Structured Clinical Interview for the DSM-5 and by [CONTACT_187919] 3 (0,1, or 2) in the Hamilton rating depression scale. • Negative pregnancy test for female participants Inclusion Criteria for healthy controls • Ages 18-65 years • Hamilton Depression Rating Scale score <8 • Capacity to understand all relevant risks and potential benefits of the study (informed consent) • Negative pregnancy test for female participants 3.2 EXCLUSION CRITERIA A potential participant who meets any of the following criteria will be excluded from participation in the study: Exclusion Criteria for individuals with depressed mood • DSM-[ADDRESS_1140595] 12 months • DSM-5 diagnosis of substance dependence (other than nicotine) within the last 12 months • DSM-5 diagnosis of substance abuse (other than nicotine or marijuana) within the last 12 months • Eating disorder (current or within the past 3 months) • Anything that, in the opi[INVESTIGATOR_871], would place the participant at increased risk or preclude the participant’s full compliance with or completion of the study • Neurological disorders, including but not limited to history of seizures (except childhood febrile seizures and ECT induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurism. • Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation • History of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation or causing cognitive sequellae • Prior brain surgery • Any brain devices/implants, including cochlear implants and aneurysm clips • Co-morbid neurological condition (i.e. seizure disorder, brain tumor) • Use of illicit drugs, confirmed by a drug test • Non-English speakers • Pregnant or nursing females 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  11 • Current use of benzodiazepi[INVESTIGATOR_22194]-epi[INVESTIGATOR_822558] • History of major neurological or psychiatric illness, including epi[INVESTIGATOR_002] • Medication use associated with neurological or psychiatric illnesses • Currently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions • First degree relative (parent, sibling, child) with major neurological or psychiatric illness • Prior brain surgery • Major head injury • Any brain devices/implants (including cochlear implants and aneurysm clips) • Use of illicit drugs, confirmed by a drug test • Braids or other hair styling that prevents direct access to the scalp (if removal not possible) • Skin allergies or very sensitive skin • Non English speakers • Pregnant or nursing females Justifications for any exclusions based on race, gender, or ethnicity: Non-English speaking individuals are excluded because the ability to accurately and completely communicate study information, answer questions about the study, and obtain consent are necessary. Justification for excluding women or women who become pregnant: Pregnant participants will be excluded despi[INVESTIGATOR_61571], since no safety data for pregnancy is known to exist for tDCS/tACS studies. We will verify pregnancy status via a urine pregnancy test for all female participants prior to receiving treatment on Day [ADDRESS_1140596]. Schiller's lab, and flyers posted at locations on campus. We have also created a social media advertisement for Facebook. We believe this multimodal approach will allow us to reach the projected number of participants. 3.3.2 RETENTION Subjects only complete a single session of the experiment. Therefore, retention is of minimal risk. When collecting data, we are mindful of the time commitment for the participant and ensure that all data is collected and procedures are carried out in a time efficient manner.  
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140597] effectiveness data for further refinement of a tACS approach and for the subsequent design of a follow-up, multi-site, large scale study. We are seeking 80 healthy participants, both male and female, between the ages of 18-65 who belong to one of two cohorts: those experiencing a depressive epi[INVESTIGATOR_822559]-matched health controls. All women of child-bearing potential will be asked to take a pregnancy test during the initial session in order to determine eligibility for the study. This is a double-blind, randomized crossover study. We estimate [ADDRESS_1140598] with 2mA amplitude. In both arms, participants will stay in a relaxed yet controlled state by [CONTACT_84022] a nature movie (“Reefscape”) during stimulation. Eligible participants will have a single visit approximately 4 hours. All time estimates take into consideration breaks and time variance in administration. 4.1 TREATMENT ASSIGNMENT PROCEDURES Participants will be randomized into one of 2 arms (see Figure 1 above). This is a double-blind study, so neither the participant nor the researcher will know which treatment the participant is receiving, if any. 4.1.1 RANDOMIZATION PROCEDURES Charles Zhou will randomize a series of 6-digit stimulation codes which will be used by [CONTACT_533479]. These stimulation codes are directly linked to which treatment participants receive (sham or tACS at IAF) at each session, and will be used with the XSCITE [ADDRESS_1140599] the following information: 1. The initial identifier codes for all potential participants 2. Stimulation code: 6-digit numerical code for the stimulation session 3. Condition number: Numerical code for the condition 4. Condition name: [CONTACT_822580] 1.0 [16-1911]  4/29/[ADDRESS_1140600] stimulation code is provided for each session. These linked codes ensure that the study coordinator and research assistants are kept blinded to which treatment each participant receives. Please see Data and Safety Monitoring for more information on unblinding this information.   
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140601] session. If a participant is determined to be ineligible, data from the screening will be retained.  Prior to attending the session, each participant will complete a screening questionnaire (online or phone) to determine preliminary eligibility. This will also include some online assessments (Structured Clinical Interview for the DSM-5 Personality Disorders Screening, as well as the Childhood Trauma Questionnaire, State-Trait Anxiety Inventory (STAI) – Trait, Rumination Scale, BIS/BAS, and Demographics). Participants are not required to fill in these prior to the initial session, but completing these assessments may reduce the duration of their session. Participants will provide verbal consent through the phone screening prior to completing these assessments. 5.2 STUDY VISITS All participants will undergo a single study visit with the same procedure; the only change will be the stimulation condition. 5.4.[ADDRESS_1140602] to determine eligibility as well. The session will begin with the Mini International Neuropsychiatric Interview (MINI) and the Hamilton Depression Rating Scale (HDRS). Both of these assessments will determine suicide risk - if the participant's responses indicate a high risk of suicide (e.g., current plans, 3 or 4 on the suicide item on the HDRS), [CONTACT_276074] will be contact[CONTACT_5365] a brief assessment and to determine the next actions to be taken (if necessary). Following these assessments, the participant will complete the Temporal Experience of Pleasure Scale (TEPS), the Snaith-Hamilton Pleasure Scale - Clinician Administered (SHAPS-C) and and the Beck Depression Inventory (BDI) prior to the stimulation. Treatment resistance will be assessed using the Maudsley Staging Method by [CONTACT_9137]. Breaks will be provided when needed. The participant will also provide a saliva sample that will be used to genotype a single polymorphism called brain derived neurotropic factor (BDNF). These assessments will be administered prior to stimulation in order to determine participant eligibility, with the MINI being used as a diagnostic tool. In total, the assessments should take approximately 1 hour to complete. If the participant is not deemed eligible, they will be compensated for their time and the visit will end. If the participant is deemed eligible, the study visit will proceed as follows. A study coordinator will apply the stimulation and EEG electrodes to the participant’s scalp. Participants will complete a 2-minute eyes closed resting state EEG recording. Participants will complete an EEG reward-processing task. Participants will be told that the better they are at this task, the more money they will earn as a "bonus". This task is visual, with participants responding to stimuli with button clicks and is expected to last about 25 minutes. Participants will then complete an emotional response EEG task, 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140603] schedule (PANAS) following this. Stimulation (tACS or sham tACS) will then be applied for [ADDRESS_1140604] the Frohlich Lab for unblinding information.    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  16 6 STUDY PROCEDURES/EVALUATIONS 6.[ADDRESS_1140605] demographics, which include medical history and medication history. In addition, several other self-report measures will be used throughout this study. These measures are listed below and can be found in the attached documents. A. THE STATE-TRAIT ANXIETY INVENTORY (STAI) is a 20-item self-report assessment that assesses either temporary or chronic anxiety. For the purposes of this study, the state version will be used to measure anxiety as a result of the stress condition. The STAI is commonly used to assess both types of anxiety, and has applications in both clinical and research settings (Spi[INVESTIGATOR_57601], 1983). B. THE BEHAVIORAL INHIBITION AND BEHAVIORAL APPROACH SYSTEM SCALES (BIS/BAS) are a set of 24 questions used to assess an individual’s sensitivity to approach vs. inhibition in motivating behavior. This scale is commonly used to measure behavior and has been demonstrated to be reliable (Carver & White, 1994).  C. THE POSITIVE AND NEGATIVE AFFECT SCHEDULE (PANAS) is a 20-item self-report assessment using a 5-level Likert scale to assess the positive and negative affect of an individual over the past week. This scale has been shown to be a reliable measure of both positive and negative affect with little subjectivity to demographic variables (Watson et al, 1988).  D. REPETITIVE THINKING QUESTIONNAIRE (RTQ) is a 22-item self-report assessment using a 4-level Likert scale to assess the frequency of repetitive negative thinking and rumination. This questionnaire has been used to assess traits of worrying about past events with transdiagnostic relevance.  E. CHILDHOOD TRAUMA QUESTIONNAIRE (CTQ) is a 28-item self-report assessment using a 5-level Likert scale to assess a history of childhood sexual, emotional, and physical abuse or neglect.  F. STATE COMPLACENCY SCALE (SCS) is a 19-item self-report assessment using a continuous analog scale to assess satisfaction with the current mood and difficulty changing mood. 6.[ADDRESS_1140606].  6.3 SAFETY MEASURES We will be monitoring the safety of our participants throughout the study with the following measures. These measures are listed below and can be found in the attached documents. A. A stimulation adverse effects questionnaire used in previous studies (IRB #14-1622, #14-3285, and #14-0600) will be administered at the end of each stimulation session. This questionnaire will be used as a safety measure and to collect data on participant experience. Please see 10.1 Safety Parameters for more information.  B. A study coordinator will be present at all times to ensure safety.   6.4 LABORATORY EVALUATIONS 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140607] an influence on effectiveness of brain stimulation. Within the central nervous system, BDNF regulates survival, proliferation, and synaptic growth as well as directly influences synaptic plasticity in the adult human brain (Antal et al., 2010). Egan et al. (2003) demonstrated that Val66Met, a single nucleotide in the BDNF gene, has function consequences in healthy humans, including decreased epi[INVESTIGATOR_83996] a reduction in recall capacity. This polymorphism is common in over one third of the Caucasian population (65% Val66Val to 35% Val66MET) (Pezawas et al, 2004; Hariri and Weinberger, 2003). Kleim et al. (2006) found that individuals with the Val/Val polymorphism respond to tDCS and transcranial magnetic stimulation (TMS) treatments with expected change, whereas, individuals expressing Val/MET allele do not. These authors indicate the difference to be caused by [CONTACT_226253]/MET allele. These findings suggest that individual efficacy of treatments using brain stimulation may be partially genetically predetermined and should be taken into account when preforming such procedures. Accordingly, we will conduct genotypi[INVESTIGATOR_533463].  We will perform exploratory analyses in which we group participants by [CONTACT_84033]. INSTRUCTIONS FOR SPECIMEN PREPARATION, HANDLING, AND STORAGE. The saliva sample will be collected using 2mL DNA collection kit from DNA Genotek. Before sample collection, it is imperative that the participant does not eat, drink, smoke or chew gum for at least 30 minutes before providing a sample.  Once the participant provides the 2mL sample, the collection tube is closed and a liquid from the lid will be released into the tube. The original lid will be removed and replaced with a small cap and the tube will be agitated for 5 seconds.  The sample is then returned to the plastic packaging and labeled with the date of collection, the study name, and the participant ID.  These samples are kept in a secure location until the completion of data collection.   
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140608] reported due to the use of transcranial brain stimulation. Previous studies in the Frohlich lab that used comparable devices (i.e., the commercial, CE-certified Neuroconn Plus stimulator) have always been classified as “non-significant risk” by [CONTACT_61598]. The Neuroconn Plus stimulator and the XCSITE100 stimulator are electrically equivalent and provide the same stimulation.  The XSCITE100 is the first non-invasive brain stimulator designed for research purposes to provide an active sham for tACS and record the stimulation output for later validation. This stimulator may apply either tDCS or tACS for up to 40 minutes (2400 seconds) with appropriate current ramp-up at the beginning of stimulation and ramp-down at the end of stimulation. Both tDCS and tACS may be applied for currents between 100 μA and 2 mA (peak-to-peak for tACS). The stimulator has two main components: 1. Android tablet with user interface application (i.e., App) 2. Stimulator with: a. Microprocessor b. Function generator chip c. Voltage controlled current source d. Safety circuitry To ensure appropriate blinding for each stimulation session, there are designated unblinded individuals to ensure the appropriate stimulation parameters are applied to each participant. These individuals will not interact with participants and will only be involved with the creation of a study file and validation of stimulation waveform. 7.[ADDRESS_1140609] the participant from high currents. The stages are as follows: 1. AUTOMATIC SOFTWARE CURRENT CUTOFF. The output of the current sensor described above is read by a microprocessor, which compares the reading to a value of ±3 mA peak. If the current exceeds these limits, 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140610]. Since high-side current sensing is used (described above), any short circuit of the electrode terminals to ground will be detected. 2. AUTOMATIC HARDWARE CURRENT CUTOFF. The output of the current sensor is fed into a pair of comparators which detect if the current exceeds ±4.[ADDRESS_1140611]-acting fuse is in series with the electrode connector. If the above two over-current detection methods fail, the fuse will below, and the stimulator will no longer be electronically connected to the device. 4. POWER SUPPLY FUSE. Finally, if for no other reason the entire device draws too much current, the main power supply fuse is blown. This fuse is sized with a cutoff of 200% of steady-state operating current.  7.[ADDRESS_1140612] measure their heads electrode placement using the 10-20 system. Participants will then be fitted with the 3 electrodes for stimulation. The participant will be in the relaxed yet, experimentally controlled state by [CONTACT_84022] a nature movie. One session of stimulation will be performed per visit for 40 minutes. During the 10 Hz tACS 
Yellow: Relay control line Green: Current through electrode (goes from negative current to zero) Blue: Current sensor output (has lowpass filter) Purple: SR latch output  
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140613] a 10 second ramp in and ramp out with 40 minutes of stimulation for a total of 2420 seconds. Stimulation waveforms are sine-waves with a peak-to-peak amplitude of 2 mA.  The sham stimulation will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 100 seconds of stimulation. Electrodes will be saline soaked, 5x5cm and placed over F3 and F4 with a 5x7cm placed over CZ as a return electrode.  Stimulation devices will be preprogrammed and codes will be randomized to one of the two experimental arms. Researchers will enter the participant-specific code into the App that controls the stimulation and monitor participants during the 40 minutes of the stimulation. The study coordinator and/or the research assistant will be thoroughly trained and have trainings documented on the transcranial stimulation device and will be present during all stimulation sessions. Please see Appendix F for an example of the training documentation log. To monitor side effects of stimulation a questionnaire will be administered after each stimulation session.  Please see Attachment [ADDRESS_1140614] Compliance for this study includes attendance of the study visit. Individuals who miss the session and are unable to reschedule will be dropped from the study.    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  21 8 POTENTIAL RISKS AND BENEFITS 8.1 BENEFITS TO SUBJECTS AND SOCIETY Our novel approach introduces non-invasive brain stimulation for mental illnesses and has the potential to treat symptoms in mood disorders. Furthermore, we will enhance the understanding of cortical network dynamics through addressing the role of modulating alpha oscillations with brain stimulation to improve symptoms in patients with mood disorders.  This study is not designed to benefit the individual participants. However, participants in this study may experience some degree of relief from mood symptoms as a result of tACS treatment.  8.2 POTENTIAL RISKS 8.2.1 PSYCHOLOGICAL Emotional Distress: We will show some images in the emotional memory task that participants might find objectionable, including sexually explicit and violent images that may be difficult to look at. Importantly, these images have been extensively used in several thousand participants in other studies and have been rated (e.g., Affective Pi[INVESTIGATOR_822560] (Lang et al., 1999), Nencki Affective Pi[INVESTIGATOR_822561] (Wierba et al., 2015; Riegel et al., 2015; Marchewka et al., 2015). We will do the following points to minimize the risk: (1) Each image is only shown for a very short time period (1 second). (2) We will provide the following information in the consent form, stressing that the participant may withdraw at any time for any reason:   If you decide to take part in this study, you will be asked to view a variety of pi[INVESTIGATOR_822562], neutral, or unpleasant. If any of the media presented should make you feel too uncomfortable to continue with the study, you are free to immediately withdraw your participation and leave without giving up payment. The content of the pi[INVESTIGATOR_822563], such as sexually explicit and violent images that may be difficult to view, which could cause emotional distress. Importantly, these images have been used extensively in several thousand participants in other studies and have been standardized by [CONTACT_822575] a validated pi[INVESTIGATOR_194035] (exemplary standardized systems used are: Affective Pi[INVESTIGATOR_822564]). We will do the following to minimize risk: (1) The images are only shown for 1 second (2) The task can be aborted early if you feel too uncomfortable during it (3) If you experience any discomfort or concerns after viewing the images, please inform the study coordinator, who can contact [CONTACT_822576].   All personnel associated with this study and who might be exposed to the images along with some example pi[INVESTIGATOR_499]. If any personnel feels too uncomfortable, they will not assist during the task and/or administer the task.  Embarrassment: Self-report assessments contain questions regarding sensitive personal information. This risk is necessary in order to assess mood symptoms and associated psychopathology. Subjects will be assured upon intake that only study personnel will see any rating form responses.  8.2.2 PHYSICAL 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  22 Risk of Injury and Discomfort: Transcranial current stimulation has been used without any reports of serious side-effects. Therefore, transcranial current stimulation represent an extremely safe and non-invasive therapeutic approach. Passing weak electric current through the scalp is also routinely done for measuring electrode resistance in all EEG recordings. Importantly, this stimulation mode has NOTHING to do with electroconvulsive therapy that applies many orders of magnitude higher stimulation current. Rather, transcranial current stimulation is so weak that it does not produce super-threshold activation of neurons (Frohlich and McCormick, 2010). Some subjects report a transient mild tingling, burning, or itching underneath the electrodes and headache, but no other side effects have been noted. There is also a rare/theoretical likelihood that stimulation of neuronal circuits can lead to epi[INVESTIGATOR_219601]. To minimize this occurrence, we screen and exclude patients with personal and family history of neurological conditions from the study. During stimulation, the research assistant will ask the subject about his/her comfort level. If the subject reports any pain, stimulation will immediately be stopped.   8.[ADDRESS_1140615] increase suicide risk. Patients with high suicide risk will not be included in this study. If an enrolled patient shows signs of suicide risks that were not apparent during enrollment, a referral to a UNC Psychiatry clinician will be required.   After obtaining participant informed consent, the Hamilton Depression Rating Scale (HDRS) will be administered, which contains a question related to suicidal thoughts/actions. If someone answers greater than 2 (i.e., either "suicidal ideas or gesture" or "attempts at suicide"), their participation in the study will be immediately stopped and [CONTACT_822582] will be contact[CONTACT_822577]. In the case that they do not see anyone for their depression, [CONTACT_822582] will assist the participant in seeking medical care.    This may include facilitating contact [CONTACT_1155]’s psychiatrist/primary care physician in order to establish a plan for safety, continued care, and follow-up. If the patient does not have an established provider, [CONTACT_822582] will assist the patient in establishing care. If at any point in the assessment, the patient is deemed to be an imminent risk of harm to self or others, study personnel will enlist the aid of campus security to ensure that the patient is safely escorted to the Emergency Department for further care.  To ensure participant comfort, a study coordinator or research assistant will periodically check in with the participant about any side-effects he/she may be experiencing. Following the conclusion of the stimulation session, the participant will receive an Adverse Effects Questionnaire to report on any of the side-effects he/she may have experienced. This questionnaire reports side-effects on a likert scale (1=Absent, 2=Mild, 3=Moderate, 4=Severe). If the participant reports side-effects of Moderate to Severe intensity, a study coordinator or research assistant will discuss the side-effects experienced, and note this response. The medical monitor will be contact[CONTACT_822578]'s verbal confirmation of intensity. 8.3.[ADDRESS_1140616] on Day 1 of Stimulation. If, after testing negative at Day 1 of Stimulation (meeting inclusion criteria), a participant reports becoming pregnant during the course of the study, she will be withdrawn from further participation. There are no plans to follow participants who become pregnant while enrolled in the study.   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  23 9 DATA AND SAFETY MONITORING 9.1 FROHLICH LAB MONITORING PLAN The purpose of this monitoring plan is to present the Frohlich Lab’s approach to monitoring clinical trials. The plan facilitates compliance with good clinical practice (GCP): a. The rights and well-being of human subjects are protected. b. The reported trial data are accurate, complete, and verifiable from source documents c. The conduct of the trial is in compliance with the currently approved protocol/amendment(s) with GCP, and with applicable regulatory requirement(s) This section identifies key monitoring activities and specifies the data to be reviewed over the course of a clinical trial. This is a single site, investigator-initiated, clinical trial, so there will be no site monitoring plan in place. The latest version of the approved IRB application for this clinical trial will be followed at all times. This responsibility falls into the hands of the study coordinator and research assistants. If at any time there is a deviation from protocol, the deviation from protocol log will be filled out. All team members will be trained on how and when to use this log. The most up-to-date IRB application will be on file in the Clinical Trials office in Room 233 of the Medical School Wing C. Deviations will be sent to the IRB every 4-6 weeks (if necessary). Periodically, study staff should review 3 randomly selected inform consent forms to ensure that (1) these forms have been filled out appropriately, and (2) the consent form process was followed and properly documented. Should any consent form be in violation, the research team will perform and document a complete review of all consent forms.  AE and SAE are clearly defined in this document. Documents of AE and SAE can be found in the study binder on file in the Clinical Trials office in Room 233 of the Medical School Wing C. It is the responsibility of the study coordinator to report all events to the PI [INVESTIGATOR_2993] a timely manner (see 9.3 Reporting Procedures). All AEs and SAEs will be discussed with the PI. For our practices, we have adapted the decision tree provided by [CONTACT_84041]-CH IRB to assist with reporting of such events. 9.2 SAFETY OVERSIGHT  Safety oversight will be under the direction of the medical monitor, who will review AEs in real time and make decisions regarding a participant’s continuation of the clinical trial. The PI [INVESTIGATOR_822565] a case-by-case basis. The medical monitor will also be present in order to discuss/explain any event(s) that may occur. 9.3 EARLY WITHDRAWAL OF PARTICIPANTS 9.3.1 REASONS FOR WITHDRAWAL A study participant will be discontinued from further participation if: • The participant fails to adhere to rules, including stress, exercise, and sleep restrictions • The participant meets any exclusion criteria (either newly developed or not previously recognized). 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  24 • Anything that, in the opi[INVESTIGATOR_871], would place the participant at increased risk or preclude the participant’s full compliance with or completion of the study. Participants are free to withdraw from participation in the study at any time upon request. 9.3.[ADDRESS_1140617] had no seizures occur (Berlim et al., 2013, Brunelin et al., 2012). The study will also be stopped (at least temporarily) if studies provide evidence that transcranial current stimulation caused brain damage or other harmful effects on subjects, either short-term or long-term. Examples of findings that might trigger a safety review are the number of SAEs overall, the number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events. The reasons for stoppi[INVESTIGATOR_84005]: • If a seizure occurs during a study visit, a temporary hold will be placed on the clinical trial The IRB will also be informed promptly and provided the reason(s) for the termination of suspension of by [CONTACT_093], as specified by [CONTACT_8146](s).   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  25 10 SAFETY & REPORTING It is important to assess safety over the course of this study. This section describes in detail how safety is assessed, reporting of Adverse Events, Serious Adverse Events, and Unanticipated Problems. This section is a reference for internal use. 10.[ADDRESS_1140618] data on participant experience. The adverse effects questionnaire asks participants to respond on a 4 point Likert scale on the severity of symptoms experienced during the stimulation session (1 = absent, 2 = mild, 3 = moderate, 4 = severe). The side effects listed are headache, neck pain, scalp pain, tingling, itching, ringing/buzzing noise, burning sensation, local redness, sleepi[INVESTIGATOR_008], trouble concentrating, improved mood, worsening of mood, dizziness, flickering lights, and other (specify). Participants are also asked to rate on a 5 point Likert scale how related they believe the side effects to be to stimulation (1 = no relation, 2 = remote, 3 = possible, 4 = probable, 5 = definite). In addition to this survey, the study coordinator or research assistant will periodically check in with the participant during the stimulation session to assess side effects.  10.2 METHODS AND TIMING FOR ASSESSING, RECORDING, AND ANALYZING SAFETY PARAMETERS 10.2.1 ADVERSE EVENTS All AEs, including local and systemic reactions not meeting the criteria for “serious adverse events”, will be captured on the appropriate CRF. In addition, the AE Report Form will be completed by [CONTACT_9137] (Appendix B). The AE Report Form includes the following: • What is known about the therapy • What is known about previous reported side effects • If the AE occurred in temporal relation to the therapy • Whether or not the AE improves or disappears when treatment is stopped • Whether the AE is worsening of baseline symptoms • Whether the AE is related to concurrent medical condition or medication use Once complete, this form will be given to the PI [INVESTIGATOR_7706]-Is, who will review, comment, and sign this form. Completed forms will be placed in the participant’s folder. In addition, the study coordinator will document any AE occurrence on the AE log (Appendix D), which includes information such as the date of the AE, severity, relationship to the treatment (assessed by [CONTACT_978] [INVESTIGATOR_7706]-Is), actions taken, and outcome(s). The log will be reviewed and initialed by [CONTACT_978] 72 hours after being completed. All AEs occurring during the clinical trial will be documented appropriately regardless of relationship to tACS. All AEs will be followed to adequate resolution and will be graded for severity and relationship to study treatment. Any medical condition noted at the initial session will be considered at baseline and not reported as an AE. All AEs will be graded for severity using the following guidelines: 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  26 • ASYMPTOMATIC. The participant is exhibiting no symptoms due to this event; no treatment needed. • MILD. Event results in mild or transient discomfort, not requiring intervention or treatment; does not limit or interfere with daily activities (e.g., insomnia, mild headache) • MODERATE. Event is sufficiently discomforting so as to limit or interfere with daily activities; may require interventional treatment (e.g., fever requiring antipyretic medication). In the case of a moderate AE, the medical advisor may recommend an over the counter medication. • SEVERE AND UNDESIRABLE. Event results in significant symptoms that prevent normal daily activities; may require hospi[INVESTIGATOR_84006] (e.g., anemia resulting in blood transfusion). Changes in the severity of an AE will be documented with the Note to File document (Appendix E) and will be filed in the participant’s folder. *Relationship to Study Products: The PI [INVESTIGATOR_7706]-Is will together determine whether an AE is associated with the study treatment. The event will be labeled associated if the event is temporally related to the administration of a therapy and no other factors can explain the event. The event will be labeled as not associated if the event is temporally independent of the study treatment and can be explained by [CONTACT_84042], such as major life events. 10.2.1 SERIOUS ADVERSE EVENTS Serious Adverse Event (SAE): An SAE, as defined by [CONTACT_18121], consists of adverse events that result in death, require either inpatient hospi[INVESTIGATOR_84007], are life-threatening, result in a persistent or significant disability/incapacity or result in congenital anomaly/birth defect.  Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant’s health is at risk and intervention is required to prevent an outcome mentioned. All SAEs will be recorded on the Serious Adverse Events Form (Appendix B), documented in the UE/SAE log and reported to the IRB.  The SAE Form will be completed by [CONTACT_9137], and includes information relating to the onset and nature of the SAE, relationship to the study treatment, seriousness of the SAE, treatment required as a response to the SAE, and outcome.  This form will be filed in the participant’s folder at the resolution of the event.  The study coordinator will complete the UE/SAE log (Appendix D) which includes information such as the date of the event, time at which the study team was informed of the event, details, when the IRB was notified, and the date that the SAE form was completed. 10.2.2 UNANTICIPATED PROBLEMS Unexpected Events (UE) will be recorded on the UE/SAE log (Appendix D) and will include information such as the date of the event, when the study team was informed of this event, details of the event, when the IRB was notified, and whether the SAE form was completed.  The IRB will be notified of each UE that may occur during the study. The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to subjects or others to include, in general, any incident, experience, or outcome that meets all of the following criteria: 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  27 • unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied; • related or possibly related to participation in the research (in the guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and • suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. If an UE occurs the IRB will be notified and the study will be adjusted as needed to protect the health and safety of the participants.  Depending on the nature of the UE, the research protocol, inclusion/exclusion criteria, and informed consent will be changed to reflect the possibility of this event reoccurring. During this time, no new participants will be recruited and the research procedures for currently enrolled participants will be stopped.  Each UE will be recorded and reported throughout the study.      10.3 REPORTING PROCEDURES We will be adopting the following table for reporting procedures: What Event is Reported When is Event Reported By [CONTACT_456107]-threatening unexpected, suspected serious adverse reactions Within 24 hours of initial receipt of information Investigator Local/internal IRBs Non-fatal, non-life threatening unexpected, suspected serious adverse reactions Within 48 hours of initial receipt of information Study Coordinator Local/internal IRBs/Institutional Officials, DSMB Unanticipated adverse device effects Within [ADDRESS_1140619] Investigator Local/internal IRBs Unanticipated problem that is not an SAE Within 7 days of the investigator becoming aware of the problem Investigator Local/internal IRBs/Institutional officials All Unanticipated Problems Within 30 days of the IRB’s receipt of the report of the UP from the investigator IRB OHRP Investigator External IRBs 10.3.[ADDRESS_1140620] tACS would interfere with pregnancy. However, should a participant become pregnant during the study, their participation will be immediately terminated and will be sent to consult with the Co-I and medical monitor. 10.4 TYPES AND DURATION OF FOLLOW-UP OF PARTICIPANTS AFTER ADVERSE EVENTS Medical monitors and Co-Is will follow up with participants within one week of an AE. 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140621]. Flavio Frohlich.   11.1 STATISTICAL ANALYSIS STRATEGIES The analysis will rely on a repeated-measures ANOVA model for the paired response [Safter, Sbefore] conditional on cohort (mood disorder vs healthy).  We will test the null hypothesis that "The mean difference (Sdiff = Safter-Sbefore) in both subpopulations is exactly zero."  The expected result is that the estimated mean difference will be large in both cohorts.  We will also test the null hypothesis that "mean Sdiff[mood disorder] is exactly equal to mean Sdiff[healthy]."  We anticipate that this test is highly likely to be inconclusive because we believe that (mean Sdiff[mood disorder] - mean Sdiff[healthy] ) is near zero or small for the target subpopulations from which we are sampling.  We will address the questions "How large is the effect of stimulation in each of the two target subpopulations?"  and "How large is the between-subpopulation difference?" Based on studies that we have described above (Neuling et al. 2013), we expect to see large effect sizes for the main effect and small effect sizes for the interaction.  Primary outcomes: • Interaction in the effect of tACS on left frontal alpha oscillation in the depressed group. Two-way interaction of within-participant factor of before/after tACS and between-participant factor of alpha-tACS/placebo. • Interaction in the effect of tACS on left frontal alpha oscillation in the healthy group. Two-way interaction of within-participant factor of before/after tACS and between-participant factor of alpha-tACS/placebo. • Three-way interaction in the effect of tACS on left frontal alpha oscillations between both groups (healthy and patient), session (before and after), and stimulation (alpha-tACS and placebo).  11.2 SAMPLE SIZE DETERMINATION Number of included participants in this experiment allows us to obtain significance (significance level 0.05) on a mixed measure ANOVA with a power of 80% for effects with a large effect size (f>=0.4). Two ANOVAs will be run, one for each group (healthy and patient):  two-way with between-participant factor stimulation (verum and sham) and within-participant factor session (before and after). We expect to see a large effect sizes when assessing the main effect session on alpha power (primary outcome). Alpha power for the 2 sessions will be highly correlated based on previous studies (r-value ~ 0.9)(Mathewson et al., 2015). Thus, we have planned to have at least 40 participants in each ANOVA (40 per group healthy and patient).   11.[ADDRESS_1140622] that is stored separately in a secured location.   
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140623] of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following: • What protected health information (PHI) will be collected from the participants in this study • Who will have access to that information and why • Who will use or disclose that information • The rights of a research subject to revoke their authorization for use of their PHI. In the event that a participant revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of participant authorization. For participants that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e., that the subject is alive) at the end of their scheduled study period. 12.2 CONFIDENTIALITY To ensure confidentiality, all data will only be referenced by a dummy identifier. Source documents (i.e. paper forms) will be kept in a locked file cabinet in a locked office. In addition, all data will be de-identified and stored on a password-protected computer. The key linking dummy identifiers with participant information will be securely located separate from all other data collected, and will never appear in an electronic format.  12.2.[ADDRESS_1140624]-protected desktop computer in the Frohlich Lab (Neuroscience Research Building 4109). 12.2.2 SENSITIVE INFORMATION Sensitive information may be collected during the screening process in order to determine eligibility (medical history, recreational drug use, etc.). Such information will be de-identified and stored in a secure, locked file cabinet, and will not be used in any further proceedings in the study. 12.2.3 OTHER Please note that there is no significant risk of deductive disclosure in this study. In addition, none of the groupi[INVESTIGATOR_61574]. 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  30 12.3 SOURCE DOCUMENTS Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents. Source data include: PARTNERS HUMAN RESEARCH COMMITTEE (IRB). • All IRB correspondences are documented • The study staff is IRB approved prior to performing any study procedures • Adverse events and deviations are reported to the IRB per current guidelines and stored appropriately • All versions of the IRB protocols and informed consent forms are on file INFORMED CONSENT. • Ensure that participant identification is not recorded on the ICF (i.e., no participant ID) • There is documentation that the participant is given a copy of the consent form • The participant and study representative signed and dated the consent form for him/herself • The participant initialed and dated all appropriate pages on the informed consent form • Note to file (Appendix F) made for any informed consent deviations • Ensure a valid (current version date) copy of the consent form was used PROTOCOL DEVIATIONS. • Any and all protocol deviations (exceptions and violations) are documented in the participant folder and reported to the IRB as required OTHER SOURCE DOCUMENTS. • Each participant folder will contain a checklist to ensure that all source documents are administered and collected properly. The checklist will be dated by [CONTACT_456110] • Review participant folders to ensure the accuracy, completeness, and legibility of the data. • Any correction made to the source documents is dated, initialed, and explained. The original entry should not be obscured. • The protocol-specific source documents are on file. • Source documents are completed in ink. • Note to files (Appendix F) are made for missing or incomplete data and to explain any discrepancies or additional comments. DNA. • Participant names will not be on any of the samples collected. DNA is sequenced to check for one nucleotide. When testing is performed, only de-identified information is shared with an outside party. This information will not be shared with anyone outside of the study personnel, including the participant.  12.4 DATA MANAGEMENT RESPONSIBILITIES The responsibilities designated to each member of the research team are documented on the Delegation of Authority Form. The study coordinator and research assistants will be responsible for the informed consent 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  31 process, review for eligibility, questionnaire administration, data entry, device administration, and CRF entries. The study coordinator will be responsible for AE/SAE documentation and reporting, while the PI [INVESTIGATOR_84009], review of the AE documentation forms, and overview of the research staff. The CTRC nurse will serve as the medical monitor for the study. 12.[ADDRESS_1140625] information such as the date the deviation occurred, details of what the deviation consisted of, any corrective and preventative actions that were taken as a result of the deviation, and the date that the PI [INVESTIGATOR_84010]. The PI [INVESTIGATOR_84011]. A completed copy of the Protocol Deviation Form will be maintained in the regulatory file, as well as in the participant’s source document. Protocol deviations will be sent to the IRB per their guidelines. The site PI/study staff will be responsible for knowing and adhering to their IRB requirements. 12.[ADDRESS_1140626] RETENTION According to the University of North Carolina at Chapel Hill’s Archives and Record Management Services schedule for General Records Retention and Disposition Schedule 6.10, records will be kept for 5 years after the completion of the study or grant end date, whichever is later.   
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140627] The investigator will ensure that this study is conducted in full conformity with the principles set forth in the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, as drafted by [CONTACT_265788] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations [ZIP_CODE] (1997). 13.[ADDRESS_1140628] (IRB) The Office of Human Research Ethics is responsible for ethical and regulatory oversight of research at UNC-Chapel Hill that involves human participants. The OHRE administers, supports, and guides the work of the Institutional Review Boards and all related activities. Any research involving human participants proposed by [CONTACT_61607], staff, or students must be reviewed and approved by [CONTACT_61608], and before related grants may be funded. OHRE and the IRBs are critical components of the coordinated Human Research Protection Program, which serves to protect the rights and welfare of human participants. All components of this program must work together to ensure institutional compliance with ethical principles and regulatory requirements. The following is a mission statement for the coordinated Human Research Protection Program: The University of North Carolina at Chapel Hill is committed to expanding and disseminating knowledge for the benefit of the people of North Carolina and the world. An important part of that commitment to knowledge is research of the highest quality on all aspects of the health and behavior of people, and such research is only possible through the participation of humans as research participants. Human participants are partners in research and a precious resource to the university. At UNC-Chapel Hill, human participant research is a privilege, but not a right. Consistent with that philosophy, it is the mission of the UNC-Chapel Hill Human Research Protection Program to ensure that: a. The rights and welfare of human participants are paramount in the research process; b. The highest standards of ethical conduct are employed in all research involving human participants; c. Research investigators are properly trained in the ethical and regulatory aspects of research with human participants; d. Research investigators deal honestly and fairly with human participants, informing them fully of procedures to be followed, and the risks and benefits of participating in research; and e. Research using human participants at UNC-CH conforms to applicable local, state, and federal laws and regulations and the policies of the university. 13.3 INFORMED CONSENT PROCESS Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of tACS will be provided to the participants. Consent forms describing, in detail, the study intervention, device, procedures, and risks are given to the participant and written documentation of informed consent is required prior to the administration of any treatment or assessments used in this study. All consent forms will be IRB-approved and updated with any new information as modifications are made throughout the study. The researcher and potential participants will review the clinical trial in its entirety by [CONTACT_456111] a private location. If the participant is unclear on any part of the consent form, the research will return 
SSDE  Version 1.0 [16-1911]  4/29/[ADDRESS_1140629]. Participants may withdraw consent at any time throughout the course of the trial.  A copy of the informed consent document will be given to the participants for their records.  13.4 EXCLUSION OF WOMEN, MINORITIES, AND CHILDREN (SPECIAL POPULATIONS) Non-English speaking individuals are excluded because the ability to accurately and complete communicate study information, answer questions about the study, and obtain consent is necessary. Female participants will be asked if there is any reason to believe they might be pregnant. Pregnant participants will be excluded despi[INVESTIGATOR_61571], since no safety data for pregnancy is known to exist for transcranial current stimulation studies. All women of child-bearing potential will be asked to take a pregnancy test during the initial session in order to determine eligibility for the study. 13.[ADDRESS_1140630] participant’s willingness to continue will be communicated within 2 days of the PI [INVESTIGATOR_61578].   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  34 14 PUBLICATION POLICY This study will be registered on clinicaltrials.gov once IRB approved. There are no restrictions on publications since this is an investigator-initiated study funded by a grant agency (NARSAD) that has no influence on the publications resulting from this study. The aim is to publish the results of this study in a peer-reviewed, highly-ranked psychiatry journal.   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  35 15 LITERATURE REFERENCES Allen, J. J. B. and S. J. Reznik (2015). "Frontal EEG asymmetry as a promising marker of depression vulnerability: summary and methodological considerations." Current Opi[INVESTIGATOR_86832] 4: 93-97. Antal, A., Chaieb, L., Moliadze, V., Monte-Silva, K., Poreisz, C., Thirugnanasambandam, N., & ... Paulus, W. (2010). Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. Brain Stimulation, 3(4), 230-237. doi:10.1016/j.brs.2009.12.003 Carver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales. Journal of Personality and Social Psychology, 67, 319-333. Craske, M. G. (2012). "The R-DoC initiative: science and practice." Depress Anxiety 29(4): 253-256. Debener, S., Beauducel, A., eacute, Nessler, D., Brocke, B., Heilemann, H., . . . rgen, u. (2000). Is resting anterior EEG alpha asymmetry a trait marker for depression? Neuropsychobiology, 41(1), 31-37. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112(2), pp. 257–269.  doi:10.1016/S0092-8674(03)[ZIP_CODE]-7 Frohlich, F. (2015). Tuning out the Blues - Thalamo-Cortical Rhythms as a Successful Target for Treating Depression. Brain Stimul. doi: 10.1016/j.brs.2015.07.040 Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003). Brain-Derived Neurotrophic Factor val⁶⁶ met Polymorphism Affects Human Memory-Related Hippocampal Activity and Predicts Memory Performance. The Journal Of Neuroscience, 23(17), 6690-6694. Helfrich, R. F., Schneider, T. R., Rach, S., Trautmann-Lengsfeld, S. A., Engel, A. K., & Herrmann, C. S. (2014). Entrainment of brain oscillations by [CONTACT_822579]. Current Biology, 24(3), 333-339. Hong, L., Walz, J. M., & Sajda, P. (2014). Your eyes give you away: prestimulus changes in pupil diameter correlate with poststimulus task-related EEG dynamics. PLoS One, 9(3), e91321. doi: 10.1371/journal.pone.0091321 Johnson, S. L., et al. (2003). "BIS/BAS levels and psychiatric disorder: An epi[INVESTIGATOR_119262]." Journal of Psychopathology and Behavioral Assessment 25(1): 25-36. Kasch, K. L., et al. (2002). "Behavioral activation and inhibition systems and the severity and course of depression." J Abnorm Psychol 111(4): 589-597. Kleim, J. A., Chan, S., Pringle, E., Schallert, K., Procaccio, V., Jimenez, R., & Cramer, S. C. (2006). BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nature Neuroscience, 9(6), 735-737. doi:10.1038/nn1699 Klimesch, W. (2012). "alpha-band oscillations, attention, and controlled access to stored information." Trends Cogn Sci 16(12): 606-617. Koss, M. C. (1986). Pupi[INVESTIGATOR_822566] 2-adrenoceptor activation. J Pharmacol Methods, 15(1), 1-19. 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  36 Leuchter, A. F., Cook, I. A., Feifel, D., Goethe, J. W., Husain, M., Carpenter, L. L., . . . George, M. S. (2015). Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimul, 8(4), 787-794. doi: 10.1016/j.brs.2015.05.005 Leuchter, A. F., Cook, I. A., Jin, Y., & Phillips, B. (2013). The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. Front Hum Neurosci, 7, 37. doi: 10.3389/fnhum.2013.[ZIP_CODE] Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A. (2015). Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments. Ann N Y Acad Sci, 1344, 78-91. doi: 10.1111/nyas.[ZIP_CODE] Mathewson, K. J., Hashemi, A., Sheng, B., Sekuler, A. B., Bennett, P. J., & Schmidt, L. A. (2015). Regional electroencephalogram (EEG) alpha power and asymmetry in older adults: a study of short-term test–retest reliability. Frontiers in aging neuroscience, 7. Murias, M., Webb, S. J., Greenson, J., & Dawson, G. (2007). Resting state cortical connectivity reflected in EEG coherence in individuals with autism. Biological psychiatry, 62(3), 270-273. Murphy, P. R., Robertson, I. H., Balsters, J. H., & O'Connell R, G. (2011). Pupi[INVESTIGATOR_822567] P3 index the locus coeruleus-noradrenergic arousal function in humans. Psychophysiology, 48(11), 1532-1543. doi: 10.1111/j.1469-8986.2011.[ZIP_CODE]. Neuling, T., Rach, S., & Herrmann, C. S. (2013). Orchestrating neuronal networks: sustained after-effects of transcranial alternating current stimulation depend upon brain states. Front Hum Neurosci, 7, 161. doi: 10.3389/fnhum.2013.0016. de Pascalis, V., et al. (2013). "Relations among EEG-alpha asymmetry, BIS/BAS, and dispositional optimism." Biol Psychol 94(1): 198-209. Pezawas L.,Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A, Weinberger D.R. (2004). “The Brain-Derived Neurotrophic Factor val66met Polymorphism and Variation in Human Cortical Morphology.” The Journal of Neuroscience 24 (45): [ZIP_CODE]–102. doi:10.1523/JNEUROSCI.2680-04.2004. Saalmann, Y. B., Pi[INVESTIGATOR_541476], M. A., Wang, L., Li, X., & Kastner, S. (2012). The pulvinar regulates information transmission between cortical areas based on attention demands. Science, 337(6095), 753-756. doi: 10.1126/science.1223082 Spi[INVESTIGATOR_2996], C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press. Thut, G., Veniero, D., Romei, V., Miniussi, C., Schyns, P., & Gross, J. (2011). Rhythmic TMS causes local entrainment of natural oscillatory signatures. Current biology : CB, 21(14), 1176-1185. doi: 10.1016/j.cub.2011.05.049 von Stein, A., & Sarnthein, J. (2000). Different frequencies for different scales of cortical integration: from local gamma to long range alpha/theta synchronization. Int J Psychophysiol, 38(3), 301-313. Vossen, A., Gross, J., & Thut, G. (2015). Alpha power increase after transcranial alternating current stimulation at alpha frequency (?-tACS) reflects plastic changes rather than entrainment. Brain stimulation, 8(3), 499-508. 
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  37 Watson, D., Clark, L. A., & Tellegan, A. (1988). Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology, 54(6), 1063–1070.    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  38 APPENDIX A: SCHEDULE OF EVENTS    Procedures Phone Screening Stimulation Day Provide Verbal Consent x  Signed Consent Form  x Assessment of Eligibility Criteria x x Urine Pregnancy Test  x Urine Drug Test  x Baseline Assessments  x Saliva Sample  x EEG during task  x EEG during rest  x Stimulation  x EEG during rest  x EEG during task  x Stimulation Questionnaire  x    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  39 APPENDIX B: AE REPORT FORM  Adverse Effects Report:  Reasons for Report (adverse event, time, date and place of occurrence if available):  1. What do we already know about the therapy? a.  2. What is the temporal relationship of the AE to the study therapy? a.  3. Does the AE improve or disappear when the therapy is stopped? a.  4. Is the AE a worsening of baseline symptom(s)? a.  5. Is the AE a result of an underlying concurrent medical condition(s) or concurrent medication(s)? a.   6. Additional Information provided by [CONTACT_84048]  a.  Research team member signature ______________________________________ Date____________ Co-Investigator:  ____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  Steps to be taken (if applicable) ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ Co-I signature _______________________________________________________Date___________  PI [CONTACT_72411]:  __________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  40 __________________________________________________________________________________________________________________________________________________________________________________________  Steps to be taken (if applicable) ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  PI [INVESTIGATOR_59844] _______________________________________________________Date___________  
  
CONFIDENTIAL  41 APPENDIX C: IRB AMENDMENT TRACKING LOG  Change Initiated By: [CONTACT_61613]: Type and Brief Summary Date Submitted to IRB Date of IRB Response Requires Stipulations? (Y/N) Requires Updated Consent Form? (Y/N) Stipulation Submission Date IRB Approval Date Initials Reference ID                                                                                                                                                 APPENDIX D: AE REPORT FORM  Participant ID Ö if AE meets definition of serious* Grade/Intensity 1. Asymptomatic 2. Mild 3. Moderate 4. Severe  Date of Incident Relationship to study device 1. Related 2. Possibly 3. Not Likely 4. Not Related Was Action Taken?     Action(s) Taken: Outcome: 1. Recovered 2. Not Recovered 3. Recovered w/Sequel 4. Fatal 5. Unknown PI [CONTACT_74938] / Date 
     Yes  /  No    
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  42 Participant ID Ö if AE meets definition of serious* Grade/Intensity 1. Asymptomatic 2. Mild 3. Moderate 4. Severe  Date of Incident Relationship to study device 1. Related 2. Possibly 3. Not Likely 4. Not Related Was Action Taken?     Action(s) Taken: Outcome: 1. Recovered 2. Not Recovered 3. Recovered w/Sequel 4. Fatal 5. Unknown PI [CONTACT_74938] / Date 
     Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No         Yes  /  No     
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  43 Appendix E: Informed Consent Quiz  Abbreviated Study Title:    Participant Name:                 [CONTACT_226270]:    Please INITIAL next to “Yes” or “No” by [CONTACT_226263] (if “No,” an explanation MUST be provided in the notes section below).  Yes  No Participant and/or the participant’s legally authorized representative (LAR) was given a copy of the consent document to read.  Yes  No Ample time was provided for reading the consent document, and the participant (or participant’s LAR) was encouraged to ask questions.  Yes  No All questions and concerns were addressed to the satisfaction of the participant (or participant’s LAR) prior to signing the consent document.  Yes  No The PI [INVESTIGATOR_54720]-I was available for questions prior to the subject signing the consent.   Yes  No The subject (or subject’s LAR) agreed to participate in the study and signed/dated the consent document.  Yes  No A copy of the signed consent document was provided to the participant (or participant’s LAR).     q Verbal consent was obtained (per IRB approved consent process).  Documentation of the process and the individual(s) witnessing the process is described below.  Yes  No No procedures specifically related to the study were performed prior to the participant signing the consent document.  The details of this research study were discussed with the participant (or participant’s LAR), including an explanation of all of the elements of the consent document.  The IRB-approved consent document was signed and dated by [CONTACT_2299] (or participant’s LAR) and a copy of the signed consent document was placed in the participant’s medical record (unless otherwise noted).  No activities specifically related to the research were initiated until after the execution of the consent document.  The principal investigator [INVESTIGATOR_226224]’s consent to be enrolled in the study and agrees with enrollment of subject. The participant (or participant’s LAR) signed consent document version      on     (date) at   (time). Notes:                                                                                                           Signature [CONTACT_822581] 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  44 APPENDIX F: NOTE TO FILE  IRB#:                         PI: [INVESTIGATOR_533476]: [Insert Short Name] Researcher: ________________            Date of Occurrence: ____________ Participant ID: _________________  Reason for Note: __________________________________________________________________________________________________________________________________________________________________________  Note: _______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  Corrective action (if applicable): _______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________   Signature: ______________________________       Date: _______________   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  45 APPENDIX G: TELEPHONE SCRIPT Telephone Consent and Screening (16-1911 Experiment 3) Date: ________________ Screening ID: _________ Criteria fulfilled: r Yes r No  Hello, my name [CONTACT_832] _________. I’m calling in regards to your interest in our study on tACS stimulation. Do you have about 10 minutes now to hear about the study, answer a few screening questions, and possibly schedule your visit?   (If ‘No’, ask for a good time to call back) (If ‘Yes’, proceed)  First, I need to ask for your verbal consent to conduct the screening interview. I will ask questions about your age, medication and drug use, and family and personal health history. You may decline to answer any questions, but please keep in mind that this may affect our ability to determine if you qualify for the study. Of course, the information you provide is strictly confidential, and will not be used for any purpose other than eligibility. Do you consent to participate in the screening interview?  (If ‘No’, thank them for their time and hang up.) (If ‘Yes’, proceed)  Great! This study is looking at how a single session of transcranial alternating current stimulation, or tACS, influences brain activity in patients with depressed mood and in non-patient controls. In this study, a weak electrical current will be applied to your scalp. Some participants have reported a mild tingling feeling while being stimulated, but no other side effects have been found. It is not a shock and should cause no pain.   This study will include a single 4 hour session. You will be compensated for your time, regardless if you qualify, with a total possible compensation of $90. We will ask that you maintain a regular sleep schedule during the study, and adhere to restrictions on exercise, caffeine, and alcohol in the day prior to the session. We will also administer a urine drug test, and female participants will be required to take a urine pregnancy test. We also administer electroencephalogram or EEG during this visit. Have you heard of EEG before? (Explain EEG if necessary, clarify, ensure participant understands). Are you still interested in participating?    (If ‘Yes’, thank them for their time) (If ‘No’, proceed)  Great! In order to make sure you are eligible for the study, I need to ask you a few questions. Please answer yes, no, I do not know, or I prefer not to answer. If you are not sure what the question is asking please ask for clarification. You do not need to provide any details in your answer.        
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  46            Age:_________   Sex:_________  1. Have you ever, or are you currently being treated for a neurological condition (i.e., epi[INVESTIGATOR_002], migraines)? r No r Yes 2. Are you currently taking medication for the treatment of depression or any other psychiatric illness? What medications are you taking? r No r Yes 3. Are you currently taking any medication for ADD or ADHD? r No r Yes 4. Are you currently diagnosed with a psychiatric illness? (Depression?) r No r Yes 5. Are you currently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD, or other behavioral conditions? r No r Yes CONTROL GROUP   a. Do you have a first degree relative (parent, sibling, or child) with a history of neurological or psychiatric illness? r No r Yes DEPRESSED GROUP   a. Have you been diagnosed with a depressive condition by a professional (i.e., a psychiatrist or licensed clinician)? r No r Yes b. Have you ever been hospi[INVESTIGATOR_057]? • If yes, was it related to depression or psychiatric illness? • If yes, when did this occur? _______________________ r No r No r Yes r Yes c. How long have you been depressed? ___________________   6. Have you ever had a traumatic brain injury or serious concussion? r No r Yes 7. Have you ever had brain surgery? r No r Yes 8. Do you have any brain devices or implants, including a cochlear implant or aneurysm clip? r No r Yes 9. Do you use any drugs, including cannabis? Please note that we will administer a urine drug test at the first session. r No r Yes Study obligations   1. Do you think you can comply with all the study duties, which include maintaining a regular sleep schedule, and no caffeine, alcohol, or excessive exercise the day before or of a session?  r No r Yes 2. We will also ask you to fill out a series of questionnaires electronically before your first session. These questionnaires will ask for information about your sleep habits, personality traits, etc. All responses will be deidentified and stored securely in the UNC REDCap system. Would you be comfortable with filling out these questionnaires? r No r Yes   
SSDE  Version 1.0 [16-1911]  4/29/19 
CONFIDENTIAL  47 APPENDIX H: TRAINING LOG Title of Training:______________________________  DATE:__________________________ By [CONTACT_31300], each staff member verifies they have been trained on the information and understand the obligations/responsibilities associated with this training. 
Trainer Name (if relevant):_____________________________ Trainer Signature (if relevant):_________________________  Training Date (if different than above) Trainee Name (please print) Trainee Signature [CONTACT_226272] (ie Presentation; Self-Study)                          